cri-one
Contents
100%
Your journey

Diabetes Research Notes and Discovery

Inventory item: 8456 | SKU: 2037 | Line: Blueprints

Page: https://cri-one.com/10-diabetes-research-notes-discovery.html

Owner and author: Christopher Gabriel Brown (CRI-ONE)

Record date: 8 October 2026

Approved public wording item: medical and regulatory wording follows D:/special/_inventory/descriptions-public/8456.md.

1. The Record in Brief

Diabetes Research Notes and Discovery (package title "Open Research: Diabetes Mechanism Analysis - Project 10") is a computational research archive: an Alchemy Data V2 search of elemental combinations against published diabetes biology, three successive literature reviews (V1 to V3, the V3 report evidence-graded), the discovery script and raw data, a 20-claim application draft and six drawings. It is a research and discovery IP record and makes no treatment claim. Its earliest dated disclosure is Deposition #201 in the 2017 catalog, with Deposition #48 printed on page 278 of Invent Depositions (ISBN 978-1-979767-89-7, first shipped 24 November 2017). The USPTO record runs from the 7 January 2026 date-stamp of U.S. Application No. 19/441,953 to three pending applications, led by U.S. Application No. 19/747,949. The item was first publicly listed on cri-one.com on 12 March 2026, and copyright arose on fixation under the notice "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved."

2. Proprietary - What Is Owned and How It Is Held

The Project 10 source folder (E4 to E10) holds 46 files: 19 Markdown documents, 8 HTML pages, 6 SVG drawings, 4 PDFs, 2 Python files, 2 JSON files, 1 ZIP snapshot, the LICENSE, CITATION.cff, CONTACT_INFO.txt and one Python cache file. The families:

  • Research text: V1, V2 and V3 known-properties reports, initial and final reports, two discovery summaries, methodology and safety statements.
  • Code and data: run_diabetes_discovery.py, config.py and the raw discovery JSON of 11 compound records.
  • Patent drafting: the 20-claim draft, claims summary, FIG. 1 to FIG. 4 and two 11x17 wall charts.
  • Briefings and filing record: three proof-of-function briefings (HTML and PDF) and the USPTO receipt for 19/747,949.

A 39-file working copy under D:/special/45-fda-rebuttles-and-adwork/ adds a regulatory memo, rebuttal notes, red-team and steelman proofs and an essay.

Sole ownership. The LICENSE (E4) declares the Work "the exclusive property of Christopher Gabriel Brown"; the USPTO receipt (E10) names him filer and first-named inventor. No assignment appears in the record.

What a buyer receives. The LICENSE: "NO LICENSE IS GRANTED. No part of this Work may be copied, modified, distributed, sublicensed, sold, published, or otherwise transferred without the express written permission of the copyright holder." The purchase term at https://cri-one.com/terms, accepted at checkout: "When you buy, you buy the use of that blueprint only."

Secrecy measures of record (18 U.S.C. 1839(3)). Full packages go only to paying buyers by private download link; the mutual NDA is published at https://cri-one.com/nda/ and quoted in delivery emails; the LICENSE heads the package "PROPRIETARY AND CONFIDENTIAL"; the public item page carries only the description.

3. First Art - The Earliest Dated Disclosure

DateRecordWhat it disclosesSource
2017 (entry's own mark)Deposition #201, 2017 catalogInsulin medicine through the auto-immune systemE1 line 871; E3
2017 (entry's own mark)Depositions #486 and #148, 2017 catalogComputational alchemy studies; healthy-human chemistryE1; E3
24 November 2017Deposition #48, Invent Depositions page 278Insulin compound designationE1 line 1179; E2
7 January 2026USPTO date-stamp, 19/441,953; V1 and V2 reportsZinc-amino acid complexes for diabetesE12; E6
12 January 2026Discovery summary and raw JSON11 compound records with scoresE6
21 February 202620-claim draft and FIG. 1-4Composition, synthesis, formulation claimsE6
12 March 2026Package snapshot; public store listingFull archive; public listingE6; E15

Report, data and draft dates above are entry dates inside the 12 March 2026 snapshot (E6); the V3 corrected report is dated 23 February 2026 on its face (E7).

Deposition anchors (master IP register E1; D:/Rebuttals/_registers/DEPOSITIONS_A.json):

  • Deposition #201 (direct; line 871; 2017 catalog, E3): "immune systemic insulin. insulin medicine to magistrate through the auto immune system". The origin-story file D:/manager/book-ocr-2017-invent-depositions/origin-stories/diabetes-mechanism-deposition-201.md names it the origin of the Project 10 line.
  • Deposition #48 (ancestor; line 1179; printed book page 278, E2): "nachmv23 insulin copyright © 2017 chris g brown".
  • Deposition #486 (ancestor; line 1186; 2017 catalog): "computational predictive plasma sorting lapidary alchemy studies".
  • Deposition #148 (ancestor; line 535; 2017 catalog): "can we figure out the chemistry in a healthy human, then make a ph balance inside each organ".

Defensive publication. Invent Depositions is an ISBN-bearing printed publication first shipped 24 November 2017 (D:/manager/book-ocr-2017-invent-depositions/MANIFEST.md); the 12 March 2026 listing put this item before the public (E15). Under 35 U.S.C. 102(a)(1) a printed publication or other public availability before a filing date is prior art against that filing; each dated public disclosure above therefore stands against every later filer on the same subject matter.

Prior Art Considered and Distinguished

Six portfolio references from the item's provenance record (D:/special/_store/manager/_store/site-deploy-2026-09-23/archive-images-fix/crione-provenance.json, SKU 2037; D:/Rebuttals/_registers/PRIOR_ART_REGISTER.json) and two literature anchors cited in the V3 report (E7).

ReferenceTitle as recordedDistinction
US 4,775,876Photon recycling light emitting diodeLED optics; no coordination chemistry
US 2012/0305059 A1Photon recycling in an optoelectronic deviceOptoelectronics; no elemental search
US 2010/0183919 A1Quantum dot ultracapacitor and electron batteryEnergy storage
US 6,175,719 B1Multi-Spot-Beam SatelliteSatellite payload
US 7,418,236 B2Extraterrestrial Communications SystemsSatellite communication
US 11,258,379 B2Quantum Noise Power DevicesEnergy harvesting
PMID: 11383627Zinc(II) Complexes of Alpha-Amino AcidsCited by the owner as validation; no computational search
PMID: 18989849Zinc(II)/Poly(gamma-glutamic acid) ComplexPolymer-carrier zinc study cited as validation

The owner's draft separates known zinc supplementation from "the specific metal-amino acid coordination complexes disclosed herein, particularly multi-mineral formulations" (20-claim draft, inside E6).

4. First to File - The USPTO Record

U.S. ApplicationFiledStatus of recordWhat it covers for this productSource
19/441,9537 January 2026Filing Receipt (Conf. [redacted]); Missing Parts notice 3 February 2026, no complete reply on fileZinc-amino acid complexes for diabetesE12
19/540,45313 February 2026Pending; Filing Receipt and corrected-papers notice 27 July 2026, reply window openUmbrella naming the disease-discovery systemsE13
19/693,40530 May 2026Pending; Filing Receipt 25 June 2026Framework umbrella; catalog lists Project 10E14
19/747,94920 July 2026Pending; acknowledgement receipt 20 July 2026 (Conf. [redacted])Claim 1 discovery method; Claim 2 seven complex familiesE10; E11

U.S. Application No. 19/747,949 was filed as "METAL-AMINO ACID COORDINATION COMPLEXES AND ALCHEMY-BASED DISCOVERY METHODOLOGY FOR TREATMENT OF DIABETES MELLITUS AND ADDITIONAL DISEASE CATEGORIES" (E10). Claim 1 is a computer-implemented method that searches an elemental probability database for candidate metal-amino acid coordination complexes for a disease target; Claim 2 sets out seven complex families, from zinc-amino acid to calcium-magnesium-zinc-amino acid (E11). The Framework catalog lists Project 10 (D:/manager/work/2 current_work_catalog.txt). U.S. Application No. 19/441,953 is a USPTO-dated record of the owner's diabetes disclosure: the 7 January 2026 date-stamp stands, and the owner relies on it as that record. Each application is dated by its own effective filing date; none is shown to carry a perfected benefit claim (D:/Rebuttals/_registers/USPTO_REGISTER.json).

Marking: Patent pending - U.S. Application No. 19/747,949 (umbrella coverage: U.S. Application Nos. 19/540,453 and 19/693,405).

5. First to Market - The Dated Public Offering

DateEventWhereSource
12 March 2026Listing "Open Research: Diabetes Mechanism Analysis" createdcri-one.com (old store)E15
19 April 2026Provenance ledger lists the item as first postedcri-one.com/store/D:/manager/first-to-market/first-to-market-LEDGER.csv
1 September 2026Blueprint record "10-diabetes-research-notes-discovery" (SKU 2037) created; the record kept in the 7 September exportcri-one.com (old store)D:/manager/export_catalog_product_20260907_110415.csv
4 September 2026Delivery file of record datedDelivery copiesD:/special/crione-static/delivery-v2/product_deliverables.csv
8 October 2026, 03:55 UTCFirst new-site email campaign to US company prospects startedcri-one.com mailD:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json; D:/special/_mailer/campaigns/new-site-2026-10/campaign.json
8 October 2026Item page publishedhttps://cri-one.com/10-diabetes-research-notes-discovery.htmlD:/special/crione-static/site-inventory/inventory/item-8456/index.html
8 October 2026, 05:06 UTCStripe card Payment Link (created 04:55:56Z) publicItem pageD:/special/crione-static/delivery-v2/payment_links_ledger.live.json; D:/Rebuttals/_registers/FIRST_TO_MARKET_REGISTER.json

6. Copyright

(c) line of record: "Copyright (c) 2026 Christopher Gabriel Brown. All rights reserved." (E4; D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json).

Works covered. Text (Markdown, HTML, briefing PDFs), drawings (four patent figures, two wall charts), code (script and configuration) and data compilations (raw discovery JSON, manifest). Copyright arose on fixation (17 U.S.C. 102(a)) and protects this expression, not the ideas or methods described (17 U.S.C. 102(b)); method and structure are held by the filings in Section 4 and by confidentiality.

Registrations of record. The owner's registered corpus comprises 20 certificates the copyright register marks verified, effective 1 October 2010 to 15 March 2026, among them TX 7-491-093, TX 8-251-642, TX 8-432-699, TX 8-657-127 and TX 9-504-677 (D:/manager/_patent_copyright_text.txt; D:/Rebuttals/_registers/COPYRIGHT_REGISTER.json). This 2026 package is protected from fixation in its own right. Registration is the gateway to suit for U.S. works (17 U.S.C. 411(a)); a certificate made within five years of first publication is prima facie evidence of validity (17 U.S.C. 410(c)).

Human authorship. Protection covers the human-authored expression and the author's selection, coordination and arrangement (U.S. Copyright Office registration guidance, March 2023). The protectable core here is human-authored: the numbered deposition texts written by Christopher Gabriel Brown, and his selection, coordination and arrangement of this package.

Notice practice. The LICENSE carries the dated notice; the product card reads "© 2026 Christopher Gabriel Brown. All rights reserved."; the 2017 entries carry "copyright © 2017 chris g brown" (E3). The notice defeats an innocent-infringer defense (17 U.S.C. 401(d)).

7. Firm Rebuttals

Challenge 1 - "Zinc for diabetes is decades old. Nothing here is original."

Rebuttal. The owner's V3 report cites the Yoshikawa/Sakurai group studies (PMID: 11383627; PMID: 18989849) as peer-reviewed validation of the zinc signal the Alchemy search identified. The original matter of record is the combination: a computer-implemented elemental-probability search (19/747,949 Claim 1), seven complex families including dual-metal and multi-mineral architectures (Claim 2), and the V1-to-V3 review trail, the V3 report evidence-graded (E7, E11). A challenger must produce a dated record, earlier than the owner's record in Section 3, disclosing that combination. None is of record.

Challenge 2 - "Someone else filed first."

Rebuttal. U.S. applications filed since 16 March 2013 are first-inventor-to-file, and every application is dated by its own effective filing date. The owner's USPTO record carries the 7 January 2026 date-stamp of 19/441,953 as a dated record of the disclosure, and the 13 February, 30 May and 20 July 2026 filing dates of the three pending applications (E10 to E14). A challenger must produce an earlier-filed application or earlier publication disclosing the same combination. None is of record. The owner's publications of 24 November 2017 and 12 March 2026 stand against every later filer on the same subject matter.

Challenge 3 - "No patent has been granted, so there is nothing to respect."

Rebuttal. "Patent pending" marking is correct while an application is pending (35 U.S.C. 292); three applications covering this product are pending of record, led by U.S. Application No. 19/747,949. Copyright protects the expression from fixation, and the LICENSE and purchase term hold the archive.

Challenge 4 - "It was released as open research, so the whole package is free to use."

Rebuttal. The Open Research Notice is the owner's own grant for educational and research use with credit, and the owner scopes it: the item page describes it as "findings-level, not archive-level", and the approved description holds the archive "Proprietary and confidential" and reads "Commercial pharmaceutical development requires separate licensing." The LICENSE of 2 May 2026 states "NO LICENSE IS GRANTED" (E4). The notice names no patent right. Publication fixes the owner's date as prior art; commercial use of the archive requires the owner's written permission.

Challenge 5 - "AI wrote these reports, so there is no copyright."

Rebuttal. Protection covers human-authored expression and the author's selection, coordination and arrangement (Copyright Office guidance, March 2023). The core is human-authored: the texts of Depositions #201, #48, #486 and #148 written by Christopher Gabriel Brown (E1), and his selection, coordination and arrangement of this package.

Challenge 6 - "The dates can be faked."

Rebuttal. The dates rest on third-party records: ISBN 978-1-979767-89-7 (CreateSpace, first shipped 24 November 2017); Internet Archive first captures of cri-one.com (28 January 2011) and buyinvent.com (5 March 2014) (D:/manager/first-to-market/wayback_evidence.json); the USPTO receipt for 19/747,949, time-stamped 07/20/2026 07:42:30 PM ET under Patent Center 79042352 with USPTO-computed SHA-512 digests (E10). Every file in Section 8 carries its SHA-256. A challenger alleging alteration must show a changed hash or a contrary third-party record. None is of record.

Challenge 7 - "This is a disease-treatment claim for an unapproved drug."

Rebuttal. The product is a research and discovery IP record and makes no treatment claim. Its public page states: "This is NOT medical advice. These compounds have NOT been clinically tested." METHODOLOGY.md defines discovery scores as "database coverage and mechanism overlap, NOT therapeutic probability" (E9). What is sold is the research archive and its patent position, not an article for ingestion.

Challenge 8 - "The scores and probabilities are invented precision."

Rebuttal. The owner's files define them as database-coverage and mechanism-overlap scores and as mathematical probabilities from the Alchemy system (E9). run_diabetes_discovery.py (E8) produces them and the raw JSON (inside E6) records them: C-H-O-N-Zn holds discovery_score 50.137852792358515 and probability 0.002757055847170317; the 12 January 2026 discovery summary gives C-H-O-N the top score, 50.5/100 (inside E6). A challenger must rerun the script on the same data and show different numbers.

Challenge 9 - "It is just an idea."

Rebuttal. The record is a working package: discovery code, an 11-record raw data set, 19 Markdown documents, six drawings, three proof-of-function briefings, a 20-claim draft and a filed application whose Claim 1 recites the computer-implemented method (E6, E11). The 12 March 2026 snapshot fixes 31 entries of that package (E6).

8. Evidence Index

#FileSHA-256 (first 16 hex)What it proves
E1D:/special/82-alchemy-calc-two/1 light trigger.txt2dcb359de3f1b56dDepositions #201, #48, #486, #148
E2D:/manager/book-ocr-2017-invent-depositions/entries-index.csv9e72c4638df2ca6e#48 on printed page 278
E3D:/manager/book-ocr-2017-invent-depositions/entries-clean.csvad3b87e885814dbb2017 catalog entries and marks
E4D:/special/10-diabetes-cure-discovery/LICENSEfd5bd7e7a66260fcNotice, ownership, no-license term
E5D:/special/10-diabetes-cure-discovery/MANIFEST.json91348d986f35db77Package manifest, 2 May 2026
E6D:/special/10-diabetes-cure-discovery/10-diabetes-cure-discovery.zipa20b0677ee0fdbd6Snapshot; entry dates from 7 January 2026
E7D:/special/10-diabetes-cure-discovery/findings/DIABETES_CURE_KNOWN_PROPERTIES_REPORT_V3.md38cd2e157b188704V3 graded report, literature anchors
E8D:/special/10-diabetes-cure-discovery/_internal/run_diabetes_discovery.pyb6a4231678a700abDiscovery script
E9D:/special/10-diabetes-cure-discovery/METHODOLOGY.md08abc89f652f8a58Definition of scores and probabilities
E10D:/special/10-diabetes-cure-discovery/N417.pdf33fc3d922864b74dUSPTO receipt, 19/747,949
E11D:/USPTO Responses/Applications/19-747-949-diabetes/PATENT_APPLICATION_DIABETES_AND_300_DISEASES.docxa1b0a541e447c03cClaims of 19/747,949
E12D:/USPTO Responses/EPSCAN/20160101_000000(23).PDF711336c95f1a261e19/441,953 Filing Receipt and notice
E13D:/USPTO Responses/EPSCAN/20160101_000000(14).PDFaa5ee1477cc821c019/540,453 Filing Receipt
E14D:/USPTO Responses/EPSCAN/20160101_000000(35).PDFb858723d9abb8e1e19/693,405 Filing Receipt
E15D:/manager/export_catalog_product_20260408_165843.csv1ec6bd9793cf5541Public listing created 12 March 2026

Full hashes: D:/Rebuttals/_evidence/8456.sha256.

9. Notice Line

© 2026 Christopher Gabriel Brown (CRI-ONE). All rights reserved. Patent pending - U.S. Application Nos. 19/747,949, 19/540,453 and 19/693,405.

This invention blueprint: Diabetes Research Notes Discovery · $982K.
cri-one.com/10-diabetes-research-notes-discovery.html
Also sold as part of Cri-One Health 2026 · $10.08B.
Payment is by bank transfer through Stripe.
Go to cart
Page 1 of 1
0% read